Board of Directors
Vice-President Development Nantworks
Dr. Raymond Hakim
Attending physician, Vanderbilt University Medical Center
Benjamin Wygodny »
Angus Partnership Inc and 3188795 Canada Inc.
Chairman of the Board
ProMetic Life Sciences Inc.
Executive Chair of Broadacre Agriculture Inc. and
Mr. G.F. Kym Anthony is an experienced and successful capital markets executive with over 30 years in the financial services and investment banking industries. He rose through the senior executive ranks of CIBC and its investment bank unit, Wood Gundy. He later became the Chair and Chief Executive Officer of TD Securities and a Vice-Chair of TD Bank, where he led the creation and development of TD Securities. Mr. Anthony was also the President and Chief Executive Officer of National Bank Financial, the investment banking and capital markets unit of National Bank of Canada for six years and CEO of Dundee Securities. Mr. Anthony has held a number of senior positions in the financial services industry, including being Chair of the Investment Dealers Association of Canada, and serves on several corporate and nonprofit boards. Mr. Anthony is also currently Executive Chair of Broadacre Agriculture and DFG Investment Advisors and a board member of ComDev International.
Mr. Anthony received his BA from Simon Fraser University and his MBA in 1980 from the University of Western Ontario where he was the gold medallist.
Michael J. Brunelle, Vice President of Development for NantWorks and Affiliated Organizations: Mr. Brunelle is a senior member of Nantwork’s business development group and serves as global head of real estate. Mr. Brunelle has completed numerous real estate and corporate transactions during his eight year tenure with NantWorks including the acquisition of pharmaceutical facilities from Watson Pharmaceuticals, Valeant Pharmaceuticals and Pfizer. Mr. Brunelle was also instrumental in launching and managing Nantwork’s heparin and biologics business. Mr. Brunelle serves on the board of directors for Strand Diagnostics, Expression Pathology and Dithera. Mr. Brunelle has over 30 years of health care experience as a consultant, investment banker and entrepreneur. Prior to his tenure with NantWorks, Mr. Brunelle was the President of Pharm Plus Resources and a Vice President of Health Care Investment Banking for Dillon Read & Co. Inc. Mr. Brunelle holds an MBA in Finance from the Wharton School of Business and a Bachelors degree from the University of California at San Diego (USA).
Other Directorships: Mr. Brunelle sits on the Board of Directors of Diagnostic ID, LLC, Expression Pathology Inc. and Dithera.
Attending Physician, Vanderbilt University Medical Center
Dr. Raymond M. Hakim, MD, PhD, is currently an Attending Physician at Vanderbilt University Medical Center. Previously, Dr. Hakim served as Chief Medical Officer and Senior Executive Vice-President, Clinical & Scientific Affairs for Fresenius Medical Services, North America until December 2011. Dr. Hakim started his career as an engineer, and received his PhD from Massachusetts Institute of Technology (MIT) in engineering in 1967. In 1972, he was accepted at McGill Medical School, completed his residency in internal medicine at the Royal Victoria Hospital in Montreal, and his Nephrology fellowship at Harvard Medical School and at Brigham and Women’s Hospital in Boston, Massachusetts in 1980. From 1980 to 1987, he served on the faculty of Harvard University and was Associated Professor of Medicine and staff at the Brigham and Women’s hospital. In 1987, Dr. Hakim served as Professor of Medicine and Director of the Clinical Division of Nephrology at the Vanderbilt University Medical School. He was also the Medical Director of the Vanderbilt Dialysis Unit. In 1995, Dr. Hakim became one of the founders of Renal Care Group, which grew to serve more than 35,000 patients and had the lowest standardized mortality among all dialysis providers. Renal Care Group which later merged with Fresenius Medical Care, North America. Dr. Hakim has spoken at hundreds of patient and health care professional meetings and has authored more than 160 articles regarding issues in dialysis. He has also contributed chapters to more than 30 medical books.Other Directorships: Dr. Hakim sits on the Public Policy Board of the American Society of Nephrology.
CTI Capital Securities Inc.
Mr. Robert Lacroix is Senior Vice-President of CTI Capital Securities Inc. Mr. Lacroix has more than 30 years of experience in the financial sector and has been working at CTI Capital Securities Inc. for 11 years. He holds a Business Degree from the École des Hautes Études Commerciales de Montréal.
During his career, Mr. Lacroix has held the position of Assistant Deputy Minister, Financing and Debt Management of the Quebec Finance Ministry. He also held numerous positions within the financial sector such as Vice-President, Finance and Administration of La Société Nationale de Fiducie and was a member of the Board of Directors of Placements SNF Inc., President of Caisses de Retraites, Portfolio Manager at the Caisse de dépôt et placement du Québec and portfolio management at the Fédération des Caisses populaires Desjardins de Montréal.
President and Chief Executive Officer
ProMetic Life Sciences Inc.
Mr. Pierre Laurin is a seasoned senior executive with more than 25 years of experience in the pharmaceutical and biotechnology industry. Involved in the development of ProMetic's platform technology since 1989, Mr. Laurin founded ProMetic Life Sciences Inc. in 1994. As CEO of the Company since its inception and Chairman unti March 2011, he took the company public on the Toronto Stock Exchange and has since raised over $400 million through equity financings and multinational funding. Mr. Laurin’s corporate development achievements include amongst others the successful close of some 35 licensing and joint venture agreements with industry leading multinationals.
Mr. Laurin’s prior experience also includes positions with various pharmaceutical companies, including Nordic Laboratories (now Sanofi-Aventis) where he played a pivotal role in the commercial success of Cardizem, Canada.
Mr. Laurin holds a B.Sc. in Pharmacy and a Masters degree in Pharmaceutical Sciences from the University of Montreal.
Groupe Méfor inc.
Ms. Ménard is President of Groupe Méfor inc. She serves on the Board of Directors of the Société des Alcools du Québec (SAQ), is Chair of its Governance and Ethics Committee, and member of its Human Resources Committee. She is Governor of the Montreal Heart Institute Foundation, sits on the Board of Directors of the On the Tip of the Toes Foundation, and is cofounder of the Quebec Breast Cancer Foundation’s Sérénité Advisory Committee. Between 2004 and 2007, Ms. Ménard served as Board member of Assuris Inc., and was member of its Corporate Governance Committee and its Communications Committee. She served on the Board of Directors of the Montreal Heart Institute Foundation from 1990 to 2006, and was Secretary and member of its Executive Committee and Human Resources Committee between 1990 and 2000. She was Chair of the Advisory Committee of Nomad Logic Inc. between 2001 and 2002, and Chairman of the Board of Directors of Alena Capital Inc. between 2000 and 2002. From 1988 to 1997, she was Vice President Corporate Affairs, Legal Affairs, and Corporate Secretary of Sodarcan Inc. She has also acted as legal counsel for various public and private corporations, including Quebecor Inc. and Loto-Quebec.
Mr. Mesburis is a Senior Portfolio Manager & Chief Compliance Officer at Excel Investment Counsel Inc. He has more than 15 years of experience in the financial services industry. His capital markets experience encompasses roles for both buy-side and sellside firms. On the buy-side, his previous roles have included Vice President and Portfolio Manager of an equity mutual fund at a Canadian public financial services company and as an Investment Manager of a mezzanine debt/private equity fund at a publicly listed Canadian bank. On the sell-side, his investment experience includes mergers and acquisitions, investment banking, and institutional equity research. His previous sell-side roles have included Vice President of Mergers & Acquisitions and Associate, Institutional Equity Research at both global and domestic bank-owned investment dealers. Mr. Mesburis is a Chartered Accountant (Ontario) and a Chartered Financial Analyst. He earned his MBA from the Schulich School of Business at York University and a B.A. from the University of Toronto.
Vice-President, Clinical Affairs - Home modalities
Dr. John Moran MD, FRACP, FACP, FACPE, currently serves as Vice President, Clinical Affairs – Home modalities at DaVita Inc. where he has overall responsibilities for quality of care and related business issues for over 15,000 home dialysis patients in over 650 care centers. Dr. Moran is also a Consulting Professor in Nephrology at Stanford University. Previously, Dr. Moran served for 8 years as Senior Vice President, Clinical Affairs for Satellite Healthcare, 4 years as Senior Vice President and Chief Medical Officer for Vasca Inc. and more than 3 years as Vice President for Clinical Development and Marketing for Baxter Healthcare Corporation.
Consultant in the energy and recycling sectors
Ms. Orr is currently a consultant. During part of 2008, she acted as Interim Chief Financial Officer for Redline Communications Inc. She also sits on the boards and various committees of Dundee Wealth Inc. and Redline Communications Inc. From 1991 to 2007, she was President of Dynamis Group Inc., a company that developed, built and operated plants in the electrical power industry and in the paper and wood recycling sectors in Europe and the U.S.A. In the past, she has sat on several public and private company boards, including Donohue Inc., the Bank of Canada, HECMontréal, Services Financiers CDPQ, Socanav Inc., Montréal Cardiology Institute and the Investment Committee of the Canada Arts Council.
Retires executive and consultant in the pharmaceutical industry
Mr. Wendel served as Vice Chairman and Chief Executive Officer of Abraxis BioScience until October 15, 2010, when Abraxis was acquired by Celgene Corporation. He formerly held the positions of Executive Vice-President of Corporate Development of Abraxis BioScience. Mr. Wendel joined American Pharmaceutical Partners (“APP”) in 2004 as Vice-President of Corporate Development. He began his 14 years with Bristol-Myers Squibb as in-house counsel before shifting to business and corporate development. While at Bristol-Myers Squibb, as Vice President, Corporate Development, International Medicines, he led teams that completed several major acquisitions, divestitures and alliances around the world. These transactions included a $225 M divestiture of Bristol's U.S. diagnostic division as well as the acquisition of three pharmaceutical firms in Argentina, South Korea, and Peru, and a co-promotion alliance with Smithkline Beecham for Avandia. Before joining APP, he served as Vice-President, Business Development and Licensing for IVAX Corporation, a generic drug manufacturer, where late last year he completed the Company's acquisition of 3M's European respiratory business. Previously, Mr. Wendel served in the legal departments of Playtex and Combe.
Mr. Wendel earned a Juris Doctorate degree from Georgetown University Law School where he was an editor of Law & Policy in International Business, and a B.S. from Cornell University.
Angus Partnership Inc. and 3188795 Canada inc.
Mr. Wygodny is the President of Angus Partnership Inc., an investment firm and of 3188795 Canada Inc., a real estate development firm.
Other Directorships: Sits on the Board of the Canadian Technion Society and is a member of the International Board of Governors of the TECHNION - The Israeli Institute of Technology.